Drug profile · INN
hexafluorenium bromide
MYLAXEN
hexafluorenium bromide (MYLAXEN) is a acetylcholinesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — hexafluorenium bromide
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
hexafluorenium bromide (MYLAXEN) is a acetylcholinesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Acetylcholinesterase inhibitor
Primary target: Acetylcholinesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is hexafluorenium bromide?
hexafluorenium bromide (MYLAXEN) is a acetylcholinesterase inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for hexafluorenium bromide?
MYLAXEN is a marketed brand name for hexafluorenium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hexafluorenium bromide?
hexafluorenium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.